Hôpital Dupuytren

InstitutionResearch output, impact & collaborations

Hôpital Dupuytren is a research organisation in Draveil, FR. OpenAlex records 6,178 works and 306,150 citations for it. 1,587 researchers list it as their most recent affiliation.

6,178

Works

306,150

Citations

1,587

Researchers

Avg h-index

IDs:ROR OpenAlex

How has Hôpital Dupuytren's publication output changed over time?

ScholarIQpublication output · 2012–2021

Output grew0% over the shown period — from 1 works in 2012 to 1 in 2021.

2012201920202021

What are the most-cited papers on Hôpital Dupuytren?

ScholarIQmost cited works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais, A. Vergnenègre, Bartomeu Massutí, Enriqueta Felip, Ramón Palmero, Ramón García-Gómez, Cinta Pallarés, José Miguel Sánchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Morán, Amelia Insa, Filippo de Marinis, R. Corre, Isabel Bover, Alfonso Illiano, Éric Dansin, Javier de Castro, Michèle Milella, Noemı́ Reguart, Giuseppe Altavilla, Ulpiano Jiménez, Mariano Provencio, Miguel Ángel Moreno, Josefa Terrasa, José Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares

The Lancet Oncology. 20125,545 CitationsOPEN ACCESS

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro, Bogdan Żurawski, Sang‐We Kim, Enric Carcereny, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Solange Peters, Konstantinos Syrigos, Fabrice Barlési, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Sridhar K. Rabindran, Ravi S. Kasinathan, Faith E. Nathan, Suresh S. Ramalingam

New England Journal of Medicine. 20192,866 CitationsOPEN ACCESS

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Wei Zou, Alan Sandler, Ida Enquist, Kimberly M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Mark L. McCleland, Simonetta Mocci, Jacek Jassem, David R. Spigel

New England Journal of Medicine. 20201,714 CitationsOPEN ACCESS

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck

Journal of Thoracic Oncology. 2021324 CitationsOPEN ACCESS